<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24083" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Latent Autoimmune Diabetes</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rajkumar </surname>
            <given-names>Venkatraman</given-names>
          </name>
          <aff>Banting Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Levine</surname>
            <given-names>Steven N.</given-names>
          </name>
          <aff>LSU Health Sciences Center Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Venkatraman Rajkumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Levine declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24083.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Latent autoimmune diabetes of adults (LADA) is an autoimmune disease that begins in adulthood and does not require insulin for glycemic control at least in the first 6 months after diagnosis. LADA shares genetic, immunologic, and metabolic features with type 1 and 2 diabetes mellitus (DM) but is often mistakenly diagnosed as type 2 diabetes (T2DM). Since several unknown factors cause LADA, lifestyle is one area that may prevent progression, much like T2DM, and lifestyle interventions are similar.</p>
        <p>This activity reviews the management of latent autoimmune diabetes and highlights the role of the interprofessional team in evaluating and treating this condition. Participating clinicians gain insight into a lesser-known subtype of diabetes, the differentiating features, and best practice guidelines for seeking endocrinology consultation. The pathophysiology of LADA and its genetic, immunologic, and metabolic similarities and differences with type 1 and type 2 diabetes are discussed. The clinical presentation of LADA, including diagnostic criteria and potential pitfalls in distinguishing it from other forms of diabetes, is presented. Furthermore, the course reviews current management approaches for LADA, including pharmacological interventions, lifestyle modifications, the role of insulin therapy, and the importance of early detection and appropriate referral to endocrinology specialists for tailored management plans. Importantly, the role of the interprofessional healthcare team in evaluating and treating LADA is emphasized throughout the activity. By fostering collaboration between primary care providers, endocrinologists, diabetes educators, and other healthcare professionals, participants will gain insights into the interprofessional approach required for optimal patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate&#x000a0;between&#x000a0;latent autoimmune diabetes of adults&#x000a0;and type 2 diabetes by incorporating autoantibody testing into diagnostic algorithms, enabling tailored treatment strategies.</p></list-item><list-item><p>Evaluate patients with latent autoimmune diabetes of adults for glycemic control, autoimmune markers, and potential complications to guide therapeutic adjustments and improve long-term outcomes.</p></list-item><list-item><p>Compare&#x000a0;the evaluation and management of latent autoimmune diabetes in adults to guide therapeutic adjustments and improve long-term outcomes.</p></list-item><list-item><p>Implement&#x000a0;care coordination amongst interprofessional team members to improve outcomes for adult patients with latent autoimmune diabetes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24083&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24083">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24083.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Diabetes mellitus (DM) is a disease spectrum ranging from classic insulinopenic type 1 diabetes (T1DM) at one end to classic insulin-resistant type 2 diabetes (T2DM) at the other. Latent autoimmune diabetes of adults (LADA) is a form of DM with features of both T1DM and T2DM and&#x000a0;is&#x000a0;termed Type 1.5 DM.<xref ref-type="bibr" rid="article-24083.r1">[1]</xref><xref ref-type="bibr" rid="article-24083.r2">[2]</xref>&#x000a0;In Japan, the synonym is slowly progressive insulin-dependent type 1 diabetes mellitus.&#x000a0;<xref ref-type="bibr" rid="article-24083.r3">[3]</xref>&#x000a0;The American Diabetes Association lists LADA as T1DM that evolves more slowly than the classic disease and does not recognize it as a specific type of DM. The World Health Organization defines LADA as slowly evolving immune-related diabetes.</p>
        <p>LADA is, by definition, a disease of adults. The Immunology for Diabetes Society has specified&#x000a0;3 criteria for the diagnosis of LADA:</p>
        <list list-type="order">
          <list-item>
            <p>&#x000a0;Age greater than 30 years</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Positive autoantibodies to islet &#x003b2; cells</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Insulin independence for at least the initial 6 months after initial diagnosis&#x000a0;<xref ref-type="bibr" rid="article-24083.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Although attractive, this set of criteria has been challenged, mainly because the choice of insulin as a treatment is highly clinician-dependent.&#x000a0;LADA is immunologically similar to T1DM as antibodies to islet &#x003b2; cells are present, albeit at lower titers, and immune destruction progresses at a much slower rate when compared to classic T1DM. Most of these patients present with hyperglycemia that is not as dramatic as T1DM and&#x000a0;is misdiagnosed and managed as T2DM. Only later is it realized that they have poor control with many conventional agents, especially sulfonylureas, and eventually require insulin therapy.</p>
        <p>LADA itself is a heterogeneous disease where some patients have high antibody titers, a low body mass index (BMI), and progress to insulin therapy fairly rapidly. Others with low antibody titers and features of insulin resistance, such as a higher BMI, progress more slowly to requiring insulin. Early recognition of LADA is paramount so that appropriate strategies are employed to delay &#x003b2;-cell destruction and reduce complications. This article reviews the advances in the pathophysiology of LADA, how to establish a diagnosis, and&#x000a0;the treatment plan.</p>
      </sec>
      <sec id="article-24083.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Genetic factors determine LADA. As in T1DM, the risk of acquiring LADA is highest in carriers of certain HLA haplotypes.<xref ref-type="bibr" rid="article-24083.r5">[5]</xref>&#x000a0;The HLA genes code for the major histocompatibility antigens with important immunoregulatory functions. Therefore, it is unsurprising that LADA is caused by dysregulated immunity. However, the precise factors that precipitate autoimmunity have not been established.</p>
        <p>Unlike T2DM, there is a lack of studies investigating the role of environmental factors like lifestyle in LADA. The reasons for this are:</p>
        <list list-type="bullet">
          <list-item>
            <p>The need for autoantibody measurement in every newly diagnosed adult diabetes patient to identify and classify patients as LADA</p>
          </list-item>
          <list-item>
            <p>The absence of comparable cohort groups</p>
          </list-item>
          <list-item>
            <p>Unavailability of lifestyle information antecedent to the diagnosis of LADA&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The inadequate sample size of LADA patients in the studies enhances the power of the study&#x000a0;<xref ref-type="bibr" rid="article-24083.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>In some studies, LADA shares several lifestyle risk factors with T2DM: excess body weight, greater waist-hip ratio, low birth weight, intake of 2 or more sweetened beverages daily, and heavy smoking. These risk factors are of greater significance in the subset of LADA with lower titers of autoantibodies and higher BMI. Although the association is less robust, these risk factors are correlated in those with higher antibody titers. Increased physical activity, moderate alcohol use, and the intake of fatty fish have a protective effect on the risk of LADA.<xref ref-type="bibr" rid="article-24083.r7">[7]</xref>&#x000a0;Two or more cups of coffee daily increase the risk for LADA, unlike the beneficial effect seen in T2DM, but this observation is sourced from a single study and needs to be validated.<xref ref-type="bibr" rid="article-24083.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24083.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Latent autoimmune disease in adults is the most frequent form of adult-onset autoimmune DM.<xref ref-type="bibr" rid="article-24083.r9">[9]</xref>&#x000a0;Geographic and ethnic differences are apparent in the incidence. In the multicentric 'Action LADA' study from Europe, 9.6% of 6156 adults with adult-onset DM had islet cell autoantibodies.<xref ref-type="bibr" rid="article-24083.r10">[10]</xref>&#x000a0;In the United Kingdom Prospective Diabetes Study, the antibody positivity among those with a presumptive diagnosis of T2DM in adults was 15%.<xref ref-type="bibr" rid="article-24083.r11">[11]</xref>&#x000a0;Similarly, studies from Norway showed a 10% incidence, whereas studies from the Middle East, Korea, and China showed between 4% and 9%.<xref ref-type="bibr" rid="article-24083.r2">[2]</xref><xref ref-type="bibr" rid="article-24083.r12">[12]</xref></p>
        <p>Most patients with LADA are positive for a single islet autoantibody; glutamic acid decarboxylase antibody is the most predominant. Some population groups have a varying prevalence of different autoantibodies, and measuring just one may underestimate the prevalence of LADA. Autoantibodies appear and disappear during longitudinal follow-up. In these situations, the role of assay interference from anti-idiotype antibodies should be considered.<xref ref-type="bibr" rid="article-24083.r12">[12]</xref>&#x000a0;A form of latent autoimmune diabetes in the young has been described.<xref ref-type="bibr" rid="article-24083.r13">[13]</xref><xref ref-type="bibr" rid="article-24083.r14">[14]</xref></p>
      </sec>
      <sec id="article-24083.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Islet &#x003b2; cell autoimmunity antedates the onset of LADA by several years. This was observed in nearly two-thirds of patients with LADA in a prospective study and substantiated autoimmunity as the first insult. This is followed by insulin resistance that causes overt hyperglycemia and the diagnosis of autoimmune insulin-independent DM. An assessment of insulin resistance using homeostatic model assessment has shown that patients with LADA have insulin resistance similar to T2DM after correction for BMI. Thus, the pathophysiology of LADA involves both autoimmunity and the metabolic derangements of insulin resistance.<xref ref-type="bibr" rid="article-24083.r15">[15]</xref></p>
        <p>Most patients with T2DM (and a lower percentage with LADA and T1DM) present with features of metabolic syndrome (MetS). The prevalence was higher in patients with LADA compared to control subjects. Eliminating glucose as a criterion, MetS remained more frequent in T2DM than in LADA, although the prevalence of those with LADA was comparable to the control subjects.<xref ref-type="bibr" rid="article-24083.r16">[16]</xref></p>
        <p>Pancreatic tissue from humans with LADA and a rat model mimicking LADA were analyzed using immunohistochemistry and PCR. Predominant macrophage (CD68) infiltration was shown in the islet cells as opposed to T1DM, which showed CD8 lymphocytes. Islet groups exist with and without infiltration. The cell type shift translated to greater interleukin-1&#x003b2; cytokine secretion and decreased expression of TNF-&#x003b1; in T lymphocytes. Also, the proliferation marker of nuclear antigen and the anti-inflammatory cytokine interleukin 10 (IL-10) were elevated, while the apoptotic promoters caspase3 and TUNEL were diminished. The result was increased &#x003b2;-cell gene transcription, greater C-peptide levels, slower progression of &#x003b2;-cell destruction, and slower onset of LADA compared to T1DM.<xref ref-type="bibr" rid="article-24083.r17">[17]</xref></p>
        <p>The presence of more than one diabetes-associated autoantibody (DAA) predicts a faster progression of &#x003b2;-cell failure. In older patients with LADA, the sensitivity of glutamic acid decarboxylase antibodies (GADA) in predicting insulin requirement diminishes.</p>
        <p>A Chinese study showed that GADA alone was insufficient to identify all cases of LADA, although it was the most dominant. This highlights the geographic and ethnic variability in the distribution of DAAs in LADA.<xref ref-type="bibr" rid="article-24083.r12">[12]</xref>&#x000a0;Anti-gliadin antibodies (IgA and IgG) increase in LADA compared to T2DM. A compromised intestinal mucosal barrier may allow environmental antigens to gain access via the oral route and initiate immunological events to induce the disease. Furthermore, unlike T1DM, anti-thyroid peroxidase antibodies are increased in LADA compared to T2DM.<xref ref-type="bibr" rid="article-24083.r18">[18]</xref><xref ref-type="bibr" rid="article-24083.r19">[19]</xref></p>
        <p>Regulatory T lymphocytes produce proteins like transcription factor forkhead box protein 3 (FOXP3), suppressing autoimmunity. Hypermethylation of DNA and decreased expression of FOXP3 diminish protection against immune destruction. FOXP3 and other proteins are lower in the high GADA subtype than the low GADA, indicating higher &#x003b2;-cell destruction in the former.<xref ref-type="bibr" rid="article-24083.r20">[20]</xref><xref ref-type="bibr" rid="article-24083.r21">[21]</xref></p>
        <p>The IgG4 class of GADA is more prevalent in LADA than in T1DM, which yields a T helper 2 lymphocyte immune response, which may be one explanation for the delayed onset of diabetes in LADA compared to T1DM. Another reason may be the binding site on the GAD molecule for the GADA. A greater degree of amino-terminal binding is apparent in LADA, whereas, in T1DM, it is in the carboxy-terminal. In the United Kingdom Prospective Diabetes Study (UKPDS), some patients who were GADA positive after 5 years did not progress to insulin requirement, and the epitope specificity may explain this. Also, a high-affinity subtype of GADA to GAD65 antigen predicts the rate of &#x003b2;-cell failure.<xref ref-type="bibr" rid="article-24083.r22">[22]</xref></p>
        <p>A variant of the IA2A antibody (256-760) is more frequently found in LADA and may prove useful in its detection.<xref ref-type="bibr" rid="article-24083.r23">[23]</xref><xref ref-type="bibr" rid="article-24083.r24">[24]</xref>&#x000a0;In the UKPDS and subsequent studies, a subset of T2DM negative for islet autoantibodies had T lymphocytes immunoreactive to islet cell antigens. The autoimmunity in these patients was more intense than in those with autoantibodies alone. They demonstrated a lower stimulated C-peptide response in this cohort, who subsequently went on to require insulin earlier than the group of T2DM without both antibodies and reactive T cells, creating a separate category of T-LADA.<xref ref-type="bibr" rid="article-24083.r25">[25]</xref><xref ref-type="bibr" rid="article-24083.r26">[26]</xref></p>
        <p>LADA shares immunological features with both T1DM and T2DM. A recent study analyzing fresh-blood-derived peripheral blood mononuclear cells showed that LADA was similar to T2DM in antigen-presenting cell characteristics and the number of regulatory B lymphocytes. In contrast, it mimicked T1DM in the number of natural killer cells.<xref ref-type="bibr" rid="article-24083.r27">[27]</xref></p>
        <p>LADA has more genetic similarity to T1DM than T2DM. Studies have shown certain HLA types increase while others decrease the risk for LADA.<xref ref-type="bibr" rid="article-24083.r5">[5]</xref>&#x000a0;Fewer 'risk alleles' in LADA explain the later onset of the disease. Genetic loci that are common in T1DM are associated with LADA. These include the major histocompatibility complex region,&#x000a0;<italic toggle="yes">PTPN22</italic>,&#x000a0;<italic toggle="yes">SH2B3</italic>, and&#x000a0;<italic toggle="yes">INS</italic>. In a recently published study, the key T2D risk allele&#x000a0;<italic toggle="yes">TCF7L2</italic>&#x000a0;had a lower occurrence in LADA cases; this locus may not play a role in the etiology of LADA.<xref ref-type="bibr" rid="article-24083.r28">[28]</xref></p>
        <p>The only genetic similarity with T2DM at the&#x000a0;<italic toggle="yes">HNF1A</italic>&#x000a0;locus was not reproduced in a subsequent study by the same investigators, who found a strong signal at the PFKFB3 locus during a landmark Genome-wide association study (GWAS).<xref ref-type="bibr" rid="article-24083.r29">[29]</xref>&#x000a0;LADA subtypes differ from GADA titers that are inversely related to BMI.<xref ref-type="bibr" rid="article-24083.r30">[30]</xref>&#x000a0;The inflammatory biomarkers associated with obesity vary when sera from various types of DM are analyzed. If these results are reproduced in larger populations, their utility to diagnose and differentiate LADA from T1DM and T2DM in conjunction with antibody testing may be enhanced.<xref ref-type="bibr" rid="article-24083.r31">[31]</xref>&#x000a0;Furthermore, a positive correlation exists in patients with LADA between BMI and interleukin-17, a pro-inflammatory cytokine from peripheral B lymphocytes implicated in T2DM and obesity.<xref ref-type="bibr" rid="article-24083.r32">[32]</xref></p>
        <p>Serious life events resulting from significant psychological stress can trigger an autoimmune response and have been associated with an increased risk of T1D in children. Similar serious life events were not identified as risk factors for the development of LADA.<xref ref-type="bibr" rid="article-24083.r33">[33]</xref>&#x000a0;Modulating the immunoreactivity of T cells may be a viable therapeutic target in LADA, just like T1DM.</p>
      </sec>
      <sec id="article-24083.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with LADA may present with symptoms of polyuria, polydipsia, nocturia, fatigue, visual changes, tingling in the feet, and weight loss or may be asymptomatic. Other factors for risk of LADA include:</p>
        <list list-type="bullet">
          <list-item>
            <p>A personal or family history of autoimmune disease should raise suspicion that a patient with hyperglycemia has LADA or T1DM.<xref ref-type="bibr" rid="article-24083.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>A history of low birth weight is a strong risk factor for both LADA and T2DM.<xref ref-type="bibr" rid="article-24083.r34">[34]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A history of smoking, alcohol consumption, and the number of sweetened beverages are risk factors.<xref ref-type="bibr" rid="article-24083.r2">[2]</xref><xref ref-type="bibr" rid="article-24083.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>The amount and type of physical activity and exercise should be sought and recorded to quantify the risk of LADA.&#x000a0;The blood pressure must be accurately measured.&#x000a0;Several diagnostic tools have been proposed to identify patients with LADA.</p>
        <p>One diagnostic screening tool with 3 criteria was used to identify LADA in diabetic patients older than 50 years of age:</p>
        <list list-type="order">
          <list-item>
            <p>A low or normal BMI</p>
          </list-item>
          <list-item>
            <p>Despite good compliance with lifestyle changes, fasting blood glucose of 270 mg/dL or higher, HbA1c 10% or greater</p>
          </list-item>
          <list-item>
            <p>Loss of weight after a diet with constant calorie content</p>
          </list-item>
        </list>
        <p>This tool was able to detect three-fourths of patients with LADA.<xref ref-type="bibr" rid="article-24083.r36">[36]</xref>&#x000a0;</p>
        <p>Foulanos et al developed the following clinical risk score:</p>
        <list list-type="order">
          <list-item>
            <p>Age&#x000a0;younger than&#x000a0;50</p>
          </list-item>
          <list-item>
            <p>Symptomatic hyperglycemia</p>
          </list-item>
          <list-item>
            <p>BMI of less than 25 kg/m<sup>2</sup></p>
          </list-item>
          <list-item>
            <p>A personal history of autoimmune disease</p>
          </list-item>
          <list-item>
            <p>A family history of autoimmune disease</p>
          </list-item>
        </list>
        <p>Two or more criteria, when positive, yielded a sensitivity of 90% and specificity of 71%, while less than 2 criteria virtually excluded LADA.<xref ref-type="bibr" rid="article-24083.r37">[37]</xref>&#x000a0;Although the above algorithms have been described and validated in some studies, it must be mentioned that the phenotypes of LADA may resemble T1DM or T2DM and, therefore, exhibit a normal or high BMI. Patients with LADA have BMI, waist circumference, blood pressure, and triglyceride levels that are midway between those with T1DM and T2DM.<xref ref-type="bibr" rid="article-24083.r38">[38]</xref></p>
        <p>Patients with LADA may have features of the MetS. Two phenotypes have been described based on GADA titers. LADA1 with cytoplasmic islet cell antibodies and high GADA titers manifesting characteristics more typical of a T1DM phenotype with lower BMI and C-peptide levels. LADA2 patients had lower GADA titers, single antibody positivity, and a phenotype more characteristic of T2DM.<xref ref-type="bibr" rid="article-24083.r39">[39]</xref>&#x000a0;Patients with LADA are usually ketosis-resistant when first diagnosed.</p>
      </sec>
      <sec id="article-24083.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When an adult patient presents with hyperglycemia with or without symptoms and is controlled without the need for insulin in the first&#x000a0;6 months, LADA should be considered. A positive antibody to one of the islet antigens is the hallmark of LADA.&#x000a0;Worldwide, the most&#x000a0;prevalent islet autoantibody utilized is GADA. Others include IA-2A, insulin antibodies, and zinc transporter isoform 8 antibody that occurs with varying frequencies.</p>
        <p>Patients with LADA have residual C-peptide levels, typically&#x000a0;between those with T1DM and T2DM. In T1DM, C-peptide is absent at first clinical presentation, and in T2DM, it is often increased. The levels of C-peptide correlate inversely with GADA titers. A stimulated C-peptide has a greater predictive value than a fasting level. The glucagon stimulation test and mixed meal tolerance test (MMTT) have been validated and useful among the methods studied. The former is shorter in duration but associated with transient nausea, while the latter takes a long time but is free of side effects. C-peptide measurement is preferable to insulin measurement as it has a longer half-life, is not subject to first-pass hepatic metabolism, and has steady-state clearance from the circulation. Insulin undergoes first-pass hepatic metabolism and has a much shorter half-life and variable clearance. Exogenously administered insulin can confound results. The MMTT has also been utilized to choose the treatment modality and predict the time to&#x000a0;transition to managing insulin.<xref ref-type="bibr" rid="article-24083.r40">[40]</xref></p>
        <p>C-peptide can be a cost-effective initial test to distinguish LADA from T2DM. Bell and Ovalle reported that C-peptide levels were significantly higher in T2DM compared to patients with LADA. All&#x000a0;patients with T2DM had normal or high C-peptide levels, but only 1 of 39 subjects with LADA had a C-peptide above the reference range. However, the diagnosis of LADA must be confirmed with antibody testing.<xref ref-type="bibr" rid="article-24083.r41">[41]</xref></p>
        <p>HLA typing is not routinely utilized in the evaluation of LADA.</p>
        <p>All other routine investigations appropriate for evaluating and managing patients with diabetes should be employed in LADA at the recommended intervals and as dictated by the clinical situation.</p>
        <p>Recommended tests include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fasting glucose</p>
          </list-item>
          <list-item>
            <p>Glycosylated hemoglobin (HbA1c)</p>
          </list-item>
          <list-item>
            <p>Self-monitoring of blood glucose&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Measures of glycemic variability, best done by continuous glucose monitoring</p>
          </list-item>
          <list-item>
            <p>Lipid profile</p>
          </list-item>
          <list-item>
            <p>Estimated glomerular filtration rate&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Serum creatinine</p>
          </list-item>
          <list-item>
            <p>Urinalysis for albumin excretion (spot and 24-hour specimen with simultaneous creatinine)</p>
          </list-item>
          <list-item>
            <p>Test for peripheral neuropathy (Semmes Weinstein monofilament test)</p>
          </list-item>
          <list-item>
            <p>Retinopathy screening by an ophthalmologist.</p>
          </list-item>
        </list>
        <p>Other tests may be indicated if diabetes-related complications develop based on individual circumstances.</p>
      </sec>
      <sec id="article-24083.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>When the diagnosis of LADA is made, non-pharmacological therapies include individualized medical nutrition and exercise plans similar to those employed in patients with T1DM and T2DM. Since LADA is a heterogeneous condition, pharmacological treatment should be personalized to gain the maximum therapeutic advantage.&#x000a0;The 2 goals of pharmacological treatment are (1) to obtain good glycemic control and (2) to prevent or delay complications. Therapies that will preserve &#x003b2;-cell function are a priority.&#x000a0;Insulin is required in most patients with LADA, may be required at the time of diagnosis in those with low C-peptide levels, and can be considered at any stage of the disease. Study results have shown preserved &#x003b2;-cell function, a stimulated C-peptide response, normal HbA1C levels, and decreased autoantibody concentrations.<xref ref-type="bibr" rid="article-24083.r42">[42]</xref></p>
        <p>The general agreement suggests that sulfonylureas are a poor choice for treating patients with LADA. Their use results in the depletion of &#x003b2;-cells, more rapid decreases in C-peptide levels, the persistence of antibodies, and earlier progression to insulin therapy.<xref ref-type="bibr" rid="article-24083.r1">[1]</xref><xref ref-type="bibr" rid="article-24083.r42">[42]</xref>&#x000a0;Although not officially approved to treat patients with LADA, metformin improves insulin sensitivity, may result in weight loss, and delay the onset of diabetic-related complications. While more studies are needed on the use of metformin, an international expert panel stated inconclusive evidence for or against the use.<xref ref-type="bibr" rid="article-24083.r1">[1]</xref></p>
        <p>Thiazolidinediones improve insulin sensitivity by activating nuclear peroxisome proliferator-activated receptors gamma receptors. Limited data is available on their use in patients with LADA. In one study, rosiglitazone preserved &#x003b2;-cell function.<xref ref-type="bibr" rid="article-24083.r43">[43]</xref>&#x000a0;However, in a small trial of only 10 patients, pioglitazone caused a more rapid decline in C-peptide levels than metformin.<xref ref-type="bibr" rid="article-24083.r44">[44]</xref>&#x000a0;More long-term studies are warranted, and clinicians need to be aware of potential side effects, including weight gain, edema, congestive heart failure, fractures, and macula edema.</p>
        <p>Dipeptidyl peptidase (DPP) 4 inhibitors have shown promise alone or when combined with insulin in preserving &#x003b2;-cell function in LADA. They affect metabolic control by prolonging endogenous glucagon-like peptide-1 (GLP1) and other peptides. Their primary action is to increase levels of GLP1, suppressing glucagon and increasing insulin secretion after a glucose load. DPP4 receptors have also been identified on the surface of T lymphocytes, where they may affect immune regulation. This latter action may be important in slowing the &#x003b2;-cell immune destruction in LADA.<xref ref-type="bibr" rid="article-24083.r45">[45]</xref>&#x000a0;Some studies with DPP4 inhibitors have demonstrated improved diabetic control and preservation of &#x003b2;-cell function.<xref ref-type="bibr" rid="article-24083.r1">[1]</xref><xref ref-type="bibr" rid="article-24083.r46">[46]</xref><xref ref-type="bibr" rid="article-24083.r47">[47]</xref><xref ref-type="bibr" rid="article-24083.r48">[48]</xref>&#x000a0;There is limited data to assess the use of GLP1 agonists in managing patients with LADA. However, dulaglutide studies have shown reductions in HbA1c levels.</p>
      </sec>
      <sec id="article-24083.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The main challenge is to distinguish patients with LADA from those with T2DM. By definition, patients with T2DM have absent autoantibodies to islet cell antigens, normal or elevated fasting, and stimulated C-peptide and usually do not require insulin for an extended period.&#x000a0;Clinicians should consider screening for LADA in patients with T2DM who do not achieve adequate glycemic control within a reasonable period&#x000a0;after compliance with therapy. This is particularly true if they are not obese, lack the features of the MetS, or they, or their first-degree relatives, have other autoimmune disorders,&#x000a0;including Hashimoto thyroiditis, Graves disease, celiac disease, rheumatoid arthritis, or pernicious anemia.<xref ref-type="bibr" rid="article-24083.r2">[2]</xref></p>
        <p>Patients with classic&#x000a0;T1DM present dramatically with ketoacidosis, need insulin at the time of presentation and are easily differentiated from LADA. At times, a young adult with maturity-onset diabetes of the young is mistakenly diagnosed as T1DM, T2DM, or LADA. MODY is rare, has a strong family history, residual C-peptide, and absent humoral and cellular immunity to islet cell antigens. It can be distinguished from LADA.</p>
      </sec>
      <sec id="article-24083.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with LADA have mortality as high as T2DM despite having more favorable metabolic parameters. In the Tr&#x000f8;ndelag Health (HUNT) study, hyperglycemia was the only significant influencing factor, not the other components of the metabolic syndrome, in determining mortality due to cardiovascular disease.<xref ref-type="bibr" rid="article-24083.r49">[49]</xref> Strict glycemic control is the key to improving the prognosis in LADA.</p>
      </sec>
      <sec id="article-24083.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Compared to those with T2DM, patients with LADA have a lower rate of microvascular complications at the time of diagnosis but an increased risk&#x000a0;during long-term follow-up. They have the same risk of cardiovascular disease as those with T2DM.<xref ref-type="bibr" rid="article-24083.r2">[2]</xref>&#x000a0;Evidence suggests that small-fiber neuropathy (SFN) occurs early and with increased frequency in LADA when compared to T2DM, which is related to higher HbA1c and poor glycemic control. Patients with LADA have severe SFN more often than those with age and duration-matched T2DM patients. However, the involvement of large nerve fibers is not different from T2DM. During the evaluation of a patient with LADA, tests to detect SFN should be included. Small nerve fibers carry pain and temperature sensations, mediate sweating, regulate vascular tone, and control blood flow. Tests for SFN include cold sensation threshold, warm sensation threshold, intraepidermal nerve fiber density (IENFD), and corneal confocal microscopy. The sensitivity of nerve conduction studies to diagnose SFN is low and not recommended.<xref ref-type="bibr" rid="article-24083.r50">[50]</xref>&#x000a0;A window of opportunity exists if detected early, as the treatment of hyperglycemia may reverse SFN and decrease morbidity.<xref ref-type="bibr" rid="article-24083.r51">[51]</xref><xref ref-type="bibr" rid="article-24083.r52">[52]</xref></p>
        <p>Long-term follow-up of patients with LADA reveals a lower risk in the first&#x000a0;9 years but a higher risk for microvascular complications in later years compared to T2DM after adjustment for several factors.<xref ref-type="bibr" rid="article-24083.r53">[53]</xref>&#x000a0;Patients with LADA have a similar degree of carotid artery atherosclerosis as T1DM and T2DM, though a better vascular risk profile.<xref ref-type="bibr" rid="article-24083.r54">[54]</xref>&#x000a0;Three studies, the Botnia study, the Freemantle diabetes study, and the HUNT study, all concurred on the increased cardiovascular disease and mortality in LADA, similar to T2DM. Therefore, LADA is associated with both microvascular and macrovascular complications, like patients with T1DM and T2DM.</p>
      </sec>
      <sec id="article-24083.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>The following consultations are recommended:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary care (family medicine, internal medicine)</p>
          </list-item>
          <list-item>
            <p>Endocrinology</p>
          </list-item>
          <list-item>
            <p>Laboratory medicine</p>
          </list-item>
          <list-item>
            <p>Clinical genetics</p>
          </list-item>
          <list-item>
            <p>Ophthalmology</p>
          </list-item>
          <list-item>
            <p>Podiatry</p>
          </list-item>
          <list-item>
            <p>Bariatric surgery</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24083.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with LADA need insight into the nature of their disease and the importance of strict glycemic control to prevent microvascular and macrovascular complications. They require the same education as those with other types of diabetes, including medical nutrition plans, medication use, glucose self-monitoring, and knowledge of recognizing and managing microvascular complications and cardiovascular disease. If patients are treated with sodium-glucose cotransporter-2 (SGLT2) inhibitors, they should be educated about the risk of ketoacidosis and the need to monitor for ketones.</p>
      </sec>
      <sec id="article-24083.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Some important pearls to consider for LADA include:</p>
        <list list-type="bullet">
          <list-item>
            <p>LADA is a form of DM with features standard to both T1DM and T2DM.</p>
          </list-item>
          <list-item>
            <p>Early diagnosis is paramount to initiating appropriate treatment and preventing complications.</p>
          </list-item>
          <list-item>
            <p>Clinicians&#x000a0;should consider screening for LADA in patients with T2DM who do not achieve adequate glycemic control within a reasonable period despite compliance with therapy. This is particularly true if they are not obese, lack the features of the MetS, or they or their first-degree relatives have other autoimmune disorders.</p>
          </list-item>
          <list-item>
            <p>New insights into LADA's pathophysiology explain &#x003b2;-cell destruction's slow progression.</p>
          </list-item>
          <list-item>
            <p>A C-peptide test, basal or after a mixed meal, may be used as an initial, cost-effective test to screen patients with LADA to identify which patients need confirmatory testing for islet autoantibodies.</p>
          </list-item>
          <list-item>
            <p>Sulfonylureas are a poor choice&#x000a0;to treat patients with LADA as they result in &#x003b2;-cell failure and a more rapid progression to the time insulin is required to control hyperglycemia.</p>
          </list-item>
          <list-item>
            <p>Insulin and DPP4 inhibitors alone and combined with insulin, thiazolidinediones, and GLP1 receptor agonists have shown promise in achieving glycemic control and preserving &#x003b2;-cell function.</p>
          </list-item>
          <list-item>
            <p>If patients are treated with SGLT2 inhibitors, they&#x000a0;should be educated about the risk of ketoacidosis and the need to monitor for ketones.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24083.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>According to the World Health Organization, there are 422 million people with&#x000a0;diabetes globally. As the prevalence of LADA in a population of T2DM is between 4% and 12%, depending on the population, approximately 17 to 50 million will have LADA. This number is likely to grow exponentially. The primary care practitioner (PCP) will likely encounter patients with LADA frequently and should be equipped with the knowledge and understanding to recognize and manage this condition promptly.</p>
        <p>The endocrinologist sees difficult and complex patients and coordinates care with the PCP, ophthalmologist, podiatrist, and geneticist. Laboratory medicine advises on the appropriateness of tests, performs biochemical and serological tests, and communicates the results to the treating clinician. Bariatric surgeons must have a high index of suspicion for LADA in patients with diabetes and counsel them regarding the less-than-optimal glycemic control post-surgery. Healthcare professionals need coordinated efforts to achieve excellent glycemic control, prevent or delay complications, and substantially reduce morbidity, mortality, and healthcare costs.</p>
      </sec>
      <sec id="article-24083.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24083&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24083">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/latent-autoimmune-diabetes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24083">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24083/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24083">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24083.s17">
        <title>References</title>
        <ref id="article-24083.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pietropaolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.</article-title>
            <source>Diabetes</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>2037</fpage>
            <page-range>2037-2047</page-range>
            <pub-id pub-id-type="pmid">32847960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maddaloni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaglia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>BO</given-names>
              </name>
            </person-group>
            <article-title>Adult-onset autoimmune diabetes.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2022</year>
            <month>Sep</month>
            <day>22</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <pub-id pub-id-type="pmid">36138034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>2461</fpage>
            <page-range>2461-2477</page-range>
            <pub-id pub-id-type="pmid">31819572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fourlanos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rolandsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Colman</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Latent autoimmune diabetes in adults (LADA) should be less latent.</article-title>
            <source>Diabetologia</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>2206</fpage>
            <page-range>2206-12</page-range>
            <pub-id pub-id-type="pmid">16193284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>HLA-DQB1 and HLA-DRB1 Variants Confer Susceptibility to Latent Autoimmune Diabetes in Adults: Relative Predispositional Effects among Allele Groups.</article-title>
            <source>Genes (Basel)</source>
            <year>2019</year>
            <month>Sep</month>
            <day>13</day>
            <volume>10</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31540313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes.</article-title>
            <source>Front Physiol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>320</fpage>
            <pub-id pub-id-type="pmid">30971952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;fvenborg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Dorkhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wolk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fatty fish consumption and risk of latent autoimmune diabetes in adults.</article-title>
            <source>Nutr Diabetes</source>
            <year>2014</year>
            <month>Oct</month>
            <day>20</day>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>e139</fpage>
            <pub-id pub-id-type="pmid">25329601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;fvenborg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Dorkhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rasouli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Storm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Coffee consumption and the risk of latent autoimmune diabetes in adults--results from a Swedish case-control study.</article-title>
            <source>Diabet Med</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>799</fpage>
            <page-range>799-805</page-range>
            <pub-id pub-id-type="pmid">24750356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laugesen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000d8;stergaard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <collab>Danish Diabetes Academy Workshop and Workshop Speakers</collab>
            </person-group>
            <article-title>Latent autoimmune diabetes of the adult: current knowledge and uncertainty.</article-title>
            <source>Diabet Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>843</fpage>
            <page-range>843-52</page-range>
            <pub-id pub-id-type="pmid">25601320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawa</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schloot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beyan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Paschou</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Leiva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yderstraede</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beck-Neilsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tuomilehto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sarti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thivolet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hadden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schernthaner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scherbaum</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <collab>Action LADA consortium</collab>
            </person-group>
            <article-title>Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.</article-title>
            <source>Diabetes Care</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>908</fpage>
            <page-range>908-13</page-range>
            <pub-id pub-id-type="pmid">23248199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zimmet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Shattock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bottazzo</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.</article-title>
            <source>Lancet</source>
            <year>1997</year>
            <month>Nov</month>
            <day>01</day>
            <volume>350</volume>
            <issue>9087</issue>
            <fpage>1288</fpage>
            <page-range>1288-93</page-range>
            <pub-id pub-id-type="pmid">9357409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Glutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5.</article-title>
            <source>Acta Diabetol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1121</fpage>
            <page-range>1121-7</page-range>
            <pub-id pub-id-type="pmid">26239144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zachariah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharfi</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Nussey</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Latent autoimmune diabetes in the young.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-3</page-range>
            <pub-id pub-id-type="pmid">18975494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Colclough</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bingley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Ellard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes.</article-title>
            <source>Diabet Med</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1028</fpage>
            <page-range>1028-33</page-range>
            <pub-id pub-id-type="pmid">21395678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiu</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Juneja</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stoever</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brooks-Worrell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-44</page-range>
            <pub-id pub-id-type="pmid">17234296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawa</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Thivolet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alemanno</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cipponeri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Leiva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <collab>Action LADA Group</collab>
            </person-group>
            <article-title>Metabolic syndrome and autoimmune diabetes: action LADA 3.</article-title>
            <source>Diabetes Care</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>160</fpage>
            <page-range>160-4</page-range>
            <pub-id pub-id-type="pmid">18945926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f6;rns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wedekind</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>J&#x000e4;hne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lenzen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pancreas Pathology of Latent Autoimmune Diabetes in Adults (LADA) in Patients and in a LADA Rat Model Compared With Type 1 Diabetes.</article-title>
            <source>Diabetes</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>624</fpage>
            <page-range>624-633</page-range>
            <pub-id pub-id-type="pmid">31974139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kucera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nov&#x000e1;kov&#x000e1;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behanov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tlaskalov&#x000e1;-Hogenov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA).</article-title>
            <source>Clin Exp Immunol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-43</page-range>
            <pub-id pub-id-type="pmid">12823288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2011</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>587</fpage>
            <page-range>587-92</page-range>
            <pub-id pub-id-type="pmid">21470281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Downregulation of T-Cell Transcription Factors in Adult Latent Autoimmune Diabetes with High-Titer Glutamic Acid Decaroxylase Antibody.</article-title>
            <source>Diabetes Ther</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>917</fpage>
            <page-range>917-927</page-range>
            <pub-id pub-id-type="pmid">30895467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Abnormal DNA methylation in CD4+ T cells from people with latent autoimmune diabetes in adults.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-8</page-range>
            <pub-id pub-id-type="pmid">21864931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landherr</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Agardh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hausmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furmaniak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rees-Smith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bonifacio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ziegler</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lernmark</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.</article-title>
            <source>Diabetes Care</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>1675</fpage>
            <page-range>1675-80</page-range>
            <pub-id pub-id-type="pmid">24598244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naik</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Brooks-Worrell</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Latent autoimmune diabetes in adults.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>94</volume>
            <issue>12</issue>
            <fpage>4635</fpage>
            <page-range>4635-44</page-range>
            <pub-id pub-id-type="pmid">19837918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiberti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bottazzo</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cucinotta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galluzzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falorni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dotta</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2.</article-title>
            <source>Diabetes</source>
            <year>2008</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>1276</fpage>
            <page-range>1276-83</page-range>
            <pub-id pub-id-type="pmid">18332100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestation and islet &#x003b2;-cell function of a subtype of latent autoimmune diabetes in adults (LADA): positive for T cell responses in phenotypic type 2 diabetes.</article-title>
            <source>Acta Diabetol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>1225</fpage>
            <page-range>1225-1230</page-range>
            <pub-id pub-id-type="pmid">31367990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Felton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Brooks-Worrell</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.</article-title>
            <source>Diabetes</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>2110</fpage>
            <page-range>2110-5</page-range>
            <pub-id pub-id-type="pmid">17473222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Espes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>St&#x000e5;lhammar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Cellular immunological changes in patients with LADA are a mixture of those seen in patients with type 1 and type 2 diabetes.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>197</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-73</page-range>
            <pub-id pub-id-type="pmid">30843600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mishra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cousminer</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hawa</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <collab>Bone Mineral Density in Childhood Study</collab>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schloot</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Yderstr&#x000e6;de</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Voight</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>SFA</given-names>
              </name>
            </person-group>
            <article-title>Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes.</article-title>
            <source>BMC Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>25</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <pub-id pub-id-type="pmid">28438156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cousminer</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Ahlqvist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Chesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hawa</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>&#x000c5;kerlund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wod</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fritsche</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f8;jlund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linneberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000e4;r&#x000e4;j&#x000e4;m&#x000e4;ki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brandslund</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rgjerd</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Brillon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Beck-Nielsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grarup</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Rickels</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ovalle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melander</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Varvel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grill</surname>
                <given-names>VER</given-names>
              </name>
              <collab>Bone Mineral Density in Childhood Study</collab>
              <name>
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Froguel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lonsdale</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schloot</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>&#x000c5;svold</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Yderstr&#x000e6;de</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Voight</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>SFA</given-names>
              </name>
            </person-group>
            <article-title>First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>2396</fpage>
            <page-range>2396-2403</page-range>
            <pub-id pub-id-type="pmid">30254083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maruyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kasuga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heterogeneity among patients with latent autoimmune diabetes in adults.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>971</fpage>
            <page-range>971-4</page-range>
            <pub-id pub-id-type="pmid">22069295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castelblanco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castelblanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gratac&#x000f2;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquerda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moll&#x000f3;</surname>
                <given-names>&#x000c0;</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez-Morros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franch-Nadal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Real</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Low-grade Inflammatory Marker Profile May Help to Differentiate Patients With LADA, Classic Adult-Onset Type 1 Diabetes, and Type 2 Diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>862</fpage>
            <page-range>862-868</page-range>
            <pub-id pub-id-type="pmid">29358494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dayal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhansali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhadada</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Peripheral blood mononuclear cells of patients with latent autoimmune diabetes secrete higher levels of pro- &#x00026; anti-inflammatory cytokines compared to those with type-1 diabetes mellitus following <italic>in vitro</italic> stimulation with &#x003b2;-cell autoantigens.</article-title>
            <source>Indian J Med Res</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>145</volume>
            <issue>6</issue>
            <fpage>767</fpage>
            <page-range>767-776</page-range>
            <pub-id pub-id-type="pmid">29067979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasouli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Hjort</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000f6;fvenborg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes.</article-title>
            <source>Diabet Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1259</fpage>
            <page-range>1259-1263</page-range>
            <pub-id pub-id-type="pmid">28632336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hjort</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Storm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Low birthweight is associated with an increased risk of LADA and type 2 diabetes: results from a Swedish case-control study.</article-title>
            <source>Diabetologia</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>11</issue>
            <fpage>2525</fpage>
            <page-range>2525-32</page-range>
            <pub-id pub-id-type="pmid">26208603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;fvenborg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Dorkhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groop</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wolk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>175</volume>
            <issue>6</issue>
            <fpage>605</fpage>
            <page-range>605-614</page-range>
            <pub-id pub-id-type="pmid">27926472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monge</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maghenzani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years.</article-title>
            <source>Diabet Med</source>
            <year>2004</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>456</fpage>
            <page-range>456-9</page-range>
            <pub-id pub-id-type="pmid">15089790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fourlanos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stankovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Colman</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>A clinical screening tool identifies autoimmune diabetes in adults.</article-title>
            <source>Diabetes Care</source>
            <year>2006</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>970</fpage>
            <page-range>970-5</page-range>
            <pub-id pub-id-type="pmid">16644622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mollo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marsal</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Esquerda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rius</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blanco-Vaca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verdaguer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Leiva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
              <collab>Action LADA 8</collab>
            </person-group>
            <article-title>Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>446</fpage>
            <page-range>446-51</page-range>
            <pub-id pub-id-type="pmid">23483713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lohmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kellner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Verlohren</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Krug</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steindorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scherbaum</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Seissler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).</article-title>
            <source>Diabetologia</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>1005</fpage>
            <page-range>1005-10</page-range>
            <pub-id pub-id-type="pmid">11484077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leighton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sainsbury</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>A Practical Review of C-Peptide Testing in Diabetes.</article-title>
            <source>Diabetes Ther</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-487</page-range>
            <pub-id pub-id-type="pmid">28484968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ovalle</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The role of C-peptide levels in screening for latent autoimmune diabetes in adults.</article-title>
            <source>Am J Ther</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-11</page-range>
            <pub-id pub-id-type="pmid">15266224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brophy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mannan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Interventions for latent autoimmune diabetes (LADA) in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Sep</month>
            <day>07</day>
            <volume>2011</volume>
            <issue>9</issue>
            <fpage>CD006165</fpage>
            <pub-id pub-id-type="pmid">21901702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-8</page-range>
            <pub-id pub-id-type="pmid">15386806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shigihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Katsuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oikawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>951</fpage>
            <page-range>951-3</page-range>
            <pub-id pub-id-type="pmid">22069291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Juli&#x000e1;n</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Carrascal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colobran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pujol-Autonell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rodriguez-Fern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teniente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mi&#x000f1;arro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruiz de Villa</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vives-Pi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puig-Domingo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8&#x0207a;T Effector Memory Subset.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>e0142186</fpage>
            <pub-id pub-id-type="pmid">26555789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pieralice</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management.</article-title>
            <source>Diabetes Metab J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>451</fpage>
            <page-range>451-464</page-range>
            <pub-id pub-id-type="pmid">30565440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maruyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yasukawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyashita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hatano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikegami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niwa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kazama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).</article-title>
            <source>Diabetes Ther</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1123</fpage>
            <page-range>1123-1134</page-range>
            <pub-id pub-id-type="pmid">28929327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>[Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine].</article-title>
            <source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>581</fpage>
            <page-range>581-4</page-range>
            <pub-id pub-id-type="pmid">15307692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Midthjell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ahlbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT Study.</article-title>
            <source>Diabetes Care</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>3971</fpage>
            <page-range>3971-8</page-range>
            <pub-id pub-id-type="pmid">24130367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkins</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bril</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Diabetic neuropathy: a review emphasizing diagnostic methods.</article-title>
            <source>Clin Neurophysiol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>114</volume>
            <issue>7</issue>
            <fpage>1167</fpage>
            <page-range>1167-75</page-range>
            <pub-id pub-id-type="pmid">12842711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jeziorska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petropoulos</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dehghani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ferdousi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponirakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Efron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Latent autoimmune diabetes of adulthood (LADA) is associated with small fibre neuropathy.</article-title>
            <source>Diabet Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>1118</fpage>
            <page-range>1118-1124</page-range>
            <pub-id pub-id-type="pmid">30575096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Petropoulos</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Jeziorska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fadavi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ponirakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tavakoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Efron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Small Fiber Neuropathy in Patients With Latent Autoimmune Diabetes in Adults.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>e102</fpage>
            <page-range>e102-3</page-range>
            <pub-id pub-id-type="pmid">26106229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maddaloni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Agbaje</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Buzzetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-215</page-range>
            <pub-id pub-id-type="pmid">32032540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24083.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valls</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ortega-Martinez de Victoria</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rubinat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Granado-Casas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mol&#x000ed;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Betriu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lecube</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Mauricio</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>28</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">28750634</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
